BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 10698055)

  • 1. Ferritin concentrations in patients with differentiated thyroid cancer.
    Lukinac L; Kalafatić D; Nöthig-Hus D; Lechpammer S; Solter M; Franceschi D; Kusić Z
    J Endocrinol Invest; 2000 Jan; 23(1):65-6. PubMed ID: 10698055
    [No Abstract]   [Full Text] [Related]  

  • 2. A low thyroglobulin level cannot be used to avoid adjuvant 131I therapy after thyroidectomy for thyroid carcinoma.
    Zanotti-Fregonara P; Grassetto G; Hindié E; Rubello D
    Eur J Nucl Med Mol Imaging; 2009 Feb; 36(2):169-71. PubMed ID: 18850097
    [No Abstract]   [Full Text] [Related]  

  • 3. Thyroglobulin before ablative radioiodine therapy.
    Grünwald F; Menzel C; Biersack HJ
    Eur J Nucl Med; 2000 Apr; 27(4):461. PubMed ID: 10805121
    [No Abstract]   [Full Text] [Related]  

  • 4. Prognostic value of postsurgical stimulated thyroglobulin levels after initial radioactive iodine therapy in well-differentiated thyroid carcinoma.
    Sawka AM; Orlov S; Gelberg J; Stork B; Dowar M; Shaytzag M; Tabatabaie V; Freeman JL; Walfish PG
    Head Neck; 2008 Jun; 30(6):693-700. PubMed ID: 18098308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated serum thyroglobulin levels at the time of ablative radioactive iodine therapy indicate a worse prognosis in thyroid cancer: an Australian retrospective cohort study.
    Matthews TJ; Chua E; Gargya A; Clark J; Gao K; Elliott M
    J Laryngol Otol; 2016 Jul; 130 Suppl 4():S50-3. PubMed ID: 27488338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic implication of thyroglobulin and quantified whole body scan after initial radioiodine therapy on early prediction of ablation and clinical response for the patients with differentiated thyroid cancer.
    Lim I; Kim SK; Hwang SS; Kim SW; Chung KW; Kang HS; Lee ES
    Ann Nucl Med; 2012 Dec; 26(10):777-86. PubMed ID: 22869417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
    Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
    Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preablative Stimulated Thyroglobulin Correlates to New Therapy Response System in Differentiated Thyroid Cancer.
    Yang X; Liang J; Li T; Zhao T; Lin Y
    J Clin Endocrinol Metab; 2016 Mar; 101(3):1307-13. PubMed ID: 26789779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of radioiodine therapy on the number of circulating epithelial cells (CEC) in patients with differentiated thyroid carcinoma - a pilot study.
    Winkens T; Pachmann K; Freesmeyer M
    Exp Clin Endocrinol Diabetes; 2014 Apr; 122(4):246-53. PubMed ID: 24771011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma.
    Giovanella L; Ceriani L; Ghelfo A; Keller F
    Clin Chem Lab Med; 2005; 43(8):843-7. PubMed ID: 16201895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of preablation stimulated thyroglobulin and thyroglobulin/thyroid-stimulating hormone ratio in differentiated thyroid cancer.
    Lin Y; Li T; Liang J; Li X; Qiu L; Wang S; Chen Y; Kang Z; Li F
    Clin Nucl Med; 2011 Dec; 36(12):1102-5. PubMed ID: 22064080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of prophylactic central compartment neck dissection on serum thyroglobulin and recommendations for adjuvant radioactive iodine in patients with differentiated thyroid cancer.
    Wang TS; Evans DB; Fareau GG; Carroll T; Yen TW
    Ann Surg Oncol; 2012 Dec; 19(13):4217-22. PubMed ID: 23010732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
    Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
    Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer.
    Padovani RP; Robenshtok E; Brokhin M; Tuttle RM
    Thyroid; 2012 Aug; 22(8):778-83. PubMed ID: 22780333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 antibody: is it an indicator of dedifferentiated thyroid cancer?
    Hasbek Z; Turgut B; Erselcan T
    Ann Nucl Med; 2014 Jan; 28(1):42-6. PubMed ID: 24234516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor (EGF) in serum of patients with differentiated carcinoma of thyroids.
    Nedvídková J; Nĕmec J; Stolba P; Vavrejnová V; Bednár J
    Neoplasma; 1992; 39(1):11-4. PubMed ID: 1528299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empiric high-dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomography scan.
    Kim WG; Ryu JS; Kim EY; Lee JH; Baek JH; Yoon JH; Hong SJ; Kim ES; Kim TY; Kim WB; Shong YK
    J Clin Endocrinol Metab; 2010 Mar; 95(3):1169-73. PubMed ID: 20080852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Warthin's tumour mimicking nodal involvement by thyroid cancer and unexplained elevation of serum thyroglobulin.
    Loo SW; Lu SJ; Geropantas K; Martin C; Roques TW
    Hell J Nucl Med; 2011; 14(2):184-5. PubMed ID: 21761028
    [No Abstract]   [Full Text] [Related]  

  • 19. [Use of serum thyroglobulin determination in the follow-up of differentiated carcinomas of the thyroid].
    Secades Ariz I; Pérez Piqueras JL; Labanda Tejedor P; Cordero Peinado J
    An Med Interna; 1988 Sep; 5(9):439-43. PubMed ID: 2856622
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical application of recombinant human thyroid-stimulating hormone in management of differentiated thyroid carcinoma].
    Liu B; Kuang A
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2012 Jun; 29(3):588-92. PubMed ID: 22826964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.